Subject
Cancer Research,Oncology,Hematology
Reference10 articles.
1. Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms: Revised Management Recommendations from European LeukemiaNet;Barbui,2018
2. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial;Al-Ali;Haematologica,2016
3. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial;Verstovsek;J. Hematol. Oncol.,2017
4. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls;Verstovsek;Blood,2012
5. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis;Vannucchi;Haematologica,2015
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献